Home > Insider Trading > Filing (0001209191-11-009398)

Filing Details

Accession Number:: 0001209191-11-009398
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-02-14 19:27:03
Reporting Period:: 2011-02-10

Filing Date:: 2011-02-14
Accepted Time:: 2011-02-14 19:27:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
892160	Derma Sciences Inc.	DSCI	Surgical & Medical Instruments & Apparatus (3841)	232328753

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1058190	F Bruce Wesson	C/O Galen Management, L.l.c. 680 Washington Blvd. Stamford CT 06901		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-02-10	50,000	$12.56	151,772	No	4	S	Indirect	See FN
Common Stock	Disposition	2011-02-11	78,220	$12.52	73,552	No	4	S	Indirect	See FN

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See FN
No	4	S	Indirect	See FN

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,125	Direct

Footnotes

The shares were sold as follows: 45,669 by Galen Partners III, L.P. ("Galen III"), 4,144 by Galen Partners International III, L.P. ("Galen International III") and 187 by Galen Employee Fund III, L.P. ("Employee Fund III").
The shares were sold at prices between $12.50 and $12.66. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 138,624 by Galen III, 12,578 by Galen International III and 570 by Employee Fund III. Claudius, L.L.C. ("Claudius") serves as the sole General Partner of Galen III and Galen International III and has sole voting and invetment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson Enterprises, Inc. ("Wesson") serves as the sole General Partner of Employee Fund III and has sole voting and investment control over the shares held by such fund and may be deemed to beneficially own the shares held by such fund. The Reporting Person is a member of Claudius and the sole shareholder of Wesson. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his pecuniary interest therein.
The shares were sold as follows: 71,444 by Galen III, 6,483 by Galen International III and 293 by Employee Fund III.
The shares were sold at prices between $12.2833 and $12.63. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 67,180 by Galen III, 6,095 by Galen International III and 277 by Employee Fund III. Claudius serves as the sole General Partner of Galen III and Galen International III and has sole voting and invetment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson serves as the sole General Partner of Employee Fund III and has sole voting and investment control over the shares held by such fund and may be deemed to beneficially own the shares held by such fund. The Reporting Person is a member of Claudius and the sole shareholder of Wesson. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his pecuniary interest therein.